MONMOUTH JUNCTION, N.J., Aug. 6, 2012 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company focused on developing inhaled therapeutics for serious diseases of the lung, today announced the election of Al Altomari to its Board of Directors, effective immediately. Insmed's Board of Directors now consists of seven members, five of whom are non-executives.
"Al brings to our Board nearly 30 years of valuable experience in the pharmaceutical industry, including more than 20 years focused on the development and marketing of specialty pharmaceutical products," said Donald J. Hayden, Insmed's Executive Chairman. "We believe his expertise in these areas will be instrumental as we continue to execute on our development plan for ARIKACE®."
Since October 2010, Mr. Altomari has served as President and Chief Executive Officer of Agile Therapeutics, a privately-held pharmaceutical company specializing in women's healthcare products, where he is also a member of the company's Board of Directors. Mr. Altomari is leading Agile through the final stages of development and commercialization of contraceptive products using the company's proprietary transdermal technology. In July of 2012, Agile completed a $40 million investment round. Prior to being named President and CEO, he served as Agile's Executive Chairman, during which time he closed a $45 million investment round in May 2010.
Before joining Agile, Mr. Altomari held multiple senior management positions over a five year period at Barrier Therapeutics. During his tenure with Barrier, he put in place the company's commercial infrastructure and all sales and marketing functions for Barrier's product portfolio, and oversaw management of all worldwide business development initiatives. In 2008, in his role as Chief Executive Officer, and as a member of the company's Board of Directors, Mr. Altomari completed the successful sale of the company to GlaxoSmithKline/Stiefel Laboratories.